Plaque Psoriasis Archives - DelveInsight

Plaque Psoriasis

recent-pharma-biotech-happenings-for-bms-prothena-canon-medical-immunovant
Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1...

Plaque psoriasis drug outshines the competition in phase III trialBristol Myers Squibb’s psoriasis drug, the TYK2 inhibitor outshone placebo and Amgen’s Otezla in a second phase 3 study, setti...


BioGen
Business Cocktail

Merck and Eisai has entered into an Oncology Pact worth Up to USD 5.76 Billion Two major pharmaceutical companies (Merck & Eisai) has entered into a USD 5.76 Billion pact to develop and commerc...


Taltz (Ixekizumab) in Treatment of Plaque psoriasis

Plaque psoriasis is a chronic autoimmune condition, with a buildup of dead cells as scales giving the affected area of skin a raised and red patchy look. About 2% of population in the US suffers fr...


Editor's Pick
Top Drugs To Watch in HIV (2025)

Human Immunodeficiency Virus or HIV is a species of Lentivirus (genus of retrovirus) th...

An in-depth Assessment of the Top Drugs Launched by Leading Global Companies ...

Progress is driven by innovation. When it comes to developing novel medications and the...

Changing Dynamics of HIV-1 Treatment Market

The HIV-1 treatment market for naïve and experienced patients is evolving consistently....

Which Countries Top the Chart in Global Pharmaceutical Market?

The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...

von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.